Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that are a major cause of mortality of Neurofibromatosis type 1 (NF1) patients. MPNST patients have few therapeutic options available and only complete surgical resection can be curative. MPNST formation and survival are dependent on activated β-catenin signaling. The goal of this study was to determine if inhibition of the CK2 enzyme can be therapeutically exploited in MPNSTs, given CK2's role in mainta ining oncogenic phenotypes including stabilization of β-catenin. We found that CK2a is over-expressed in MPNSTs and is critical for maintaining cell survival, as the CK2 inhibitor, CX-4945 (Silmitasertib), and shRNA targeting CK2a each significantly reduce MPNST cell viability. These effects were preceded by loss of critical signaling pathways in MPNSTs, including destabilization of β-catenin and TCF8. CX-4945 administration in vivo slowed tumor growth and extends survival time. We conclude that CK2 inhibition is a promising approach to blocking β-catenin in MPNST cells, although combinatorial therapies may be required for maximal efficacy.
|Original language||English (US)|
|Number of pages||13|
|State||Published - Aug 1 2016|
Bibliographical noteFunding Information:
This work was supported by grants from the National Institutes of Health 1R21NS084885-01A1 (NR and TPC), R01NS086219 (NR and DAL), and NS28840 (NR). The Cincinnati Children's Hospital Research Foundation, Flow Cytometry, Pathology, and Viral Vector Cores provided partial support for these studies (NIH P30 DK, 090971055).
- G2 arrest